- Remunity™ (treprostinil)
-
Product
Remunity™
(treprostinil)Therapeutic Platform
Remodulin®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Please click here to see important safety information
Status
Devices / Commercially launched U.S. sales Feb 2021 - Implantable System for Remodulin® (treprostinil)
-
Therapeutic Platform
Remodulin®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Please click here to see important safety information
Status
Devices / FDA Approved*Implantable System for intravenous delivery of Remodulin® (treprostinil).
*FDA requires that certain conditions of Medtronic’s PMA approval of the Implantable System for Remodulin must be satisfied prior to launch or sale of the Implantable System for Remodulin; accordingly, Implantable System for Remodulin labeling may be revised in the process of satisfying such conditions of approval.
LEARN MORE Close - Tyvaso DPI™ (inhaled treprostinil)
-
Therapeutic Platform
Tyvaso®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Pulmonary Hypertension (PH) WHO Group 3Status
Phase 3Dry Powder Inhaled (DPI) treprostinil in a small handheld device for the treatments of pulmonary arterial hypertension (PAH), and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
LEARN MORE Close - Trevyent® (treprostinil sodium)
-
Product
Trevyent®
(treprostinil sodium)Therapeutic Platform
Remodulin®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Devices / Preparing NDA ResubmissionPrefilled, pre-programmed, single-use PatchPump® for subcutaneous administration of treprostinil.
LEARN MORE Close - RemoLife (treprostinil)
-
Product
RemoLife
(treprostinil)Therapeutic Platform
Remodulin®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Devices / Prototype development - OreniPro™ (once-daily, oral treprostinil prodrug)
-
Therapeutic Platform
Orenitram®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Phase 1Oral prodrug being developed to provide increased tolerability and convenience through a once-daily dosing regimen.
LEARN MORE Close - RemoPro™ (treprostinil prodrug)
-
Product
RemoPro™
(treprostinil prodrug)Therapeutic Platform
Remodulin®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Phase 1Prodrug of treprostinil that is being developed to reduce site pain associated with subcutaneous delivery of treprostinil.
LEARN MORE Close - ADVANCE Studies Ralinepag (IP receptor agonist)
-
Therapeutic Platform
NCE / Novel BiologicsTargeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Phase 3An IP receptor agonist that is a next-generation, once-a-day oral therapy that targets the prostacyclin pathway for patients with pulmonary arterial hypertension (PAH).
LEARN MORE Close - SAPPHIRE Aurora-GT™ eNOS Gene Therapy
-
Therapeutic Platform
NCE / Novel BiologicsTargeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Registration phase studyRegistration phase study in Canada to establish the efficacy and safety of repeat dosing of autologous endothelial progenitor cells (EPCs) transfected with human endothelial nitric oxide synthase (eNOS) and expanded ex-vivo in patients with PAH on top of conventional treatments.
LEARN MORE Close - Genetically-Enhanced Mesenchymal stem cells (GEM)
-
Therapeutic Platform
NCE / Novel BiologicsTargeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH) / SepsisStatus
Pre-clinicalEnhanced Mesenchymal stem cells for the treatment of sepsis and pulmonary arterial hypertension (PAH).
LEARN MORE Close
Menu